Selank — questions, answered plainly.

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the immunopeptide tuftsin. It is primarily characterised in rodent behavioural models (anxiety, stress, withdrawal) and in vitro neurochemistry assays.

Tuftsin is an endogenous tetrapeptide (Thr-Lys-Pro-Arg) cleaved from immunoglobulin G. Selank extends the tuftsin sequence with a Pro-Gly-Pro stabilising tail to improve metabolic stability for research use.

GABA is the main inhibitory neurotransmitter in the central nervous system. A positive allosteric modulator increases the binding or activity of GABA at its receptors. In vitro brain-membrane studies have described Selank in this role. The relevance of in vitro modulation to behavioural or clinical outcomes is not established.

The PubMed-indexed work cited on this profile is in vitro and rat-model research. Controlled human clinical-trial data on Selank are not cited here.

Rat models of unpredictable chronic mild stress (Kasian et al. 2017) and naloxone-precipitated morphine withdrawal (Konstantinopolsky et al. 2022), plus in vitro [³H]GABA binding in rat brain-membrane preparations (Vyunova et al. 2018).

Primary literature concentrates within a small set of research groups (mainly Russian). Findings are model-specific and not equivalent to controlled clinical-trial evidence in international peer-reviewed databases.